<DOC>
	<DOCNO>NCT02622022</DOCNO>
	<brief_summary>36 patient interstitial lung disease randomize 1 week treatment morphine hydrochloride oral linctus 5 mg , four time day , 5 mg need 4 time day , correspond dos placebo . VAS score dyspnea evaluate 1 hour 1 week follow . Other questionnaire also evaluate ( GAD-7 , K-BUILD , Leicester score )</brief_summary>
	<brief_title>Palliation Dyspnea With Morphine Patients With Interstitial Lung Disease</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Dyspnea</mesh_term>
	<mesh_term>Lung Diseases , Interstitial</mesh_term>
	<mesh_term>Morphine</mesh_term>
	<criteria>A diagnosis interstitial lung disease ( IPF , NSIP , RAILS , SclILS , MCTDILS , asbestous , drug induce ILD , unclassified ILD ) Dyspnea correspond Medial Research Councils ( MRC ) dyspnea score ≥ 3 Written consent Age ≥ 18 year Competent For fertile woman : Negative pregnancy test For fertile sexually active participant : Use safe anticonceptionals Ongoing infection Decreased lung function degree make form respiratory depression life threaten Treatment morphine morphine analogue Allergy towards morphine hydrochloride</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>110 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>randomise</keyword>
	<keyword>placebo control</keyword>
	<keyword>clinical trial</keyword>
</DOC>